Should I Buy MREO Stock in 2026?

Data-driven analysis and honest assessment for Mereo BioPharma Group PLC ADR

Analysis Updated:
CAUTIONSeveral concerns warrant careful consideration

Current Price: $0.57

Decision Score

4.0/10

Weak

Based on 6 fundamental factors

Score Breakdown:

Valuation (20%)5/10

P/E data not available

Growth (20%)5/10

Growth data limited

Profitability (20%)2/10

Currently unprofitable

Financial Health (15%)5/10

Financial health data limited

Cash Flow (15%)2/10

Negative free cash flow

Insider Activity (10%)5/10

No recent insider activity

Key Investment Metrics

Current Price

$0.57

P/E Ratio

N/A

Revenue Growth

N/A

Profit Margin

N/A

Market Cap

$0.1B

Dividend Yield

None

How MREO Compares to Competitors

Understanding how MREO stacks up against peers helps inform your investment decision.

How MREO Compares to Peers

Upcoming Events for MREO

+5 Reasons TO Buy MREO

1. High gross margins of 73%

strong

Gross margins above 50% typically indicate strong brand value or intellectual property moats.

-5 Reasons NOT to Buy MREO

1. Negative free cash flow

high risk

Burning cash creates funding risk and limits shareholder returns.

2. Small-cap volatility risk

high risk

Market cap under $2B means higher volatility and lower liquidity.

3. Minimal revenue growth

low risk

Growth of 0.0% barely keeps pace with inflation.

Who Should Buy MREO?

Investment Profile

Risk Level

Very High

Recommended Holding Period

3-5 years

Best For:

    Not Suitable For:

    • Growth Investors

      Limited 0% growth may disappoint

    • Income-Focused Retirees

      No dividend paid

    • Risk-Averse Investors

      Very High risk may cause uncomfortable volatility

    • Large Position Traders

      Lower liquidity may impact execution

    Consider These Alternatives

    If you're interested in MREO, compare these Healthcare peers:

    Pro tip: Compare MREO directly with competitors using our comparison tool to see which stock better fits your criteria.

    Get the Full Picture

    Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for MREO

    Frequently Asked Questions

    What is MREO stock price today?

    MREO (Mereo BioPharma Group PLC ADR) stock is trading at $0.57 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

    Is MREO stock going up or down today?

    MREO stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

    Should I buy MREO stock now?

    The decision to buy MREO depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

    Is MREO a buy, hold, or sell right now?

    Our AI-powered analysis provides buy/hold/sell recommendations for MREO based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

    Is MREO stock overvalued or undervalued?

    Use our DCF valuation calculator to determine if MREO is overvalued or undervalued based on fundamental analysis and future cash flow projections.

    What is MREO's P/E ratio?

    P/E ratio data for MREO will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

    What is MREO's market cap?

    MREO (Mereo BioPharma Group PLC ADR) has a market capitalization of $0.09 billion, making it a small-cap stock.

    What is MREO's price to book ratio?

    MREO trades at a price-to-book (P/B) ratio of 1.94, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

    Similar Investment Decisions

    Explore investment analyses for stocks similar to Mereo BioPharma Group PLC ADR

    Explore Categories

    Disclaimer

    This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.